Autres langues Cyclerion Therapeutics, Inc.

Actions

CYCN

US23255M2044

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
2,93 ^USD	-3,62 %		-16,29 %	-12,54 %

05/03	Cyclerion Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
2023	Cyclerion Therapeutics, Inc. nomme Regina Graul présidente	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
Cyclerion Appoints Regina Graul, Ph.D., as President	04/12
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	04/12
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	01/12
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	01/12
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	24/11
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	23/10/23
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	01/08/23
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31/07/23
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	31/07/23
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	31/07/23
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	28/07/23
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	27/06/23
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	01/06/23
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	01/06/23
Cyclerion Therapeutics : Private Placement - Form 8-K	25/05/23
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	25/05/23
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	25/05/23
Cyclerion Therapeutics to Implement 1-for-20 Reverse Stock Split	15/05/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cyclerion Therapeutics, Inc.

Actions

CYCN

US23255M2044

Autres langues

Filtres